A retrospective review of the metabolic syndrome in women diagnosed with breast cancer and correlation with estrogen receptor.

PubWeight™: 0.81‹?›

🔗 View Article (PMC 4586082)

Published in Breast Cancer Res Treat on October 02, 2011

Authors

Sarah V Colonna1, L Douglas Case, Julia A Lawrence

Author Affiliations

1: Vanderbilt University Medical Center, Nashville, TN, USA. sarah.v.colonna@vanderbilt.edu

Articles cited by this

Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28

Prevalence of overweight and obesity in the United States, 1999-2004. JAMA (2006) 72.59

Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med (2003) 35.39

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation (2009) 35.24

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA (2002) 25.68

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA (2006) 24.01

The obesity epidemic in the United States--gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol Rev (2007) 16.67

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res (2004) 16.51

Adiponectin and adiponectin receptors. Endocr Rev (2005) 8.46

Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat (2010) 4.58

Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54

Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst (1994) 4.28

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol (2008) 4.24

Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res (2007) 3.97

Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol (2010) 3.92

Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol (2010) 3.75

Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology (2011) 3.24

Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev (2006) 2.99

Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer (2004) 2.96

Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes (2003) 2.76

A population-based assessment of specialty physician involvement in cancer clinical trials. J Natl Cancer Inst (2011) 2.48

Molecular links between obesity and breast cancer. Endocr Relat Cancer (2006) 2.44

Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res (2003) 2.35

Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol (2010) 2.26

Adiposity, the metabolic syndrome, and breast cancer in African-American and white American women. Endocr Rev (2007) 1.98

A meta-analysis of body mass index and risk of premenopausal breast cancer. Epidemiology (1995) 1.70

Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Curr Neuropharmacol (2006) 1.53

Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer. Breast Cancer Res Treat (2005) 1.51

The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast Cancer Res Treat (2010) 1.50

Hormone receptor status of breast tumors in black, Hispanic, and non-Hispanic white women. An analysis of 13,239 cases. Cancer (1996) 1.48

Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case-control study. Nutr Metab Cardiovasc Dis (2009) 1.43

Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience. Cancer Biol Ther (2010) 1.43

The association of metabolic syndrome with triple-negative breast cancer. Breast Cancer Res Treat (2009) 1.40

Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev (2004) 1.39

A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.22

Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer. Clin Oncol (R Coll Radiol) (2010) 1.17

Insulin resistance, obesity and breast cancer risk. Maturitas (2008) 1.08

Introducing molecular subtyping of breast cancer into the clinic? J Clin Oncol (2009) 1.01

Diagnostic criteria for metabolic syndrome: a comparative analysis in an unselected sample of adult male population. Metabolism (2008) 0.91

Obesity is associated with breast cancer in African-American women but not Hispanic women in South Los Angeles. Cancer (2011) 0.90